In Vivo Study of Local Tranexamic Acid Concentrations Following Intra-Articular Administration in Total Knee Arthroplasty
Launched by VALDOLTRA ORTHOPEDIC HOSPITAL · Mar 9, 2025
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosis of advanced osteoarthritis of the knee joint
- Exclusion Criteria:
- • known allergy to TXA
- • family history or past spontaneous thromboembolic event
- • pathological preoperative blood analysis
- • advanced heart failure (NYHA \> 2)
- • ischemic heart disease
- • epilepsy
About Valdoltra Orthopedic Hospital
Valdoltra Orthopedic Hospital is a leading medical institution specializing in orthopedic care and innovative research. Renowned for its commitment to advancing orthopedic practices, the hospital conducts clinical trials aimed at evaluating new treatments, surgical techniques, and rehabilitation methods. With a team of experienced professionals and a state-of-the-art facility, Valdoltra fosters a collaborative environment that prioritizes patient safety and outcomes. The hospital's dedication to excellence in clinical research contributes significantly to the advancement of orthopedic medicine, ensuring that patients receive the most effective and evidence-based care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ankaran, Ajdovscina, Slovenia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported